Profluent has published research in Nature describing the development of OpenCRISPR-1, a gene editor designed entirely using artificial intelligence. The AI-generated protein, also referred to as PF-CAS-182, was created by training large language models on over 1 million CRISPR operons from 26 terabases of genomic data. OpenCRISPR-1 is 1,380 residues in length and differs from SpCas9 by 403 mutations. Experimental results showed that OpenCRISPR-1 has comparable or improved genome editing activity and specificity relative to SpCas9, with sharply reduced off-target effects and lower immunogenicity. The protein is compatible with base editing systems and effective across a range of genomic targets, including those with different protospacer-adjacent motif (PAM) sequences. OpenCRISPR-1 and its supporting data have been released under open access, with plasmids available through Addgene (IDs 221565, 221566, 221567) to facilitate broad research and commercial use. In a separate development, Timeless Biotech has introduced the MenoTime platform, a machine learning-based tool for predicting ovarian aging and menopause timing. The MenoTime algorithm performs over 100,000 conditional evaluations per prediction, analyzing more than 40,000 clinical data points, including hormone levels, demographic, and lifestyle variables. The platform provides personalized estimates of ovarian age and identifies key drivers of menopausal timing for women's health and longevity.